International Clinical Trial: Bronchoscopic Tumour Ablation for Immune Priming to Enhance Neoadjuvant Chemotherapy and Immunotherapy in Resectable Non-Small Cell Lung Cancer (IMPRINT Study): A Single-Arm Open Label Feasibility Study

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ACTRN12626001210369) titled 'Bronchoscopic Tumour Ablation for Immune Priming to Enhance Neoadjuvant Chemotherapy and Immunotherapy in Resectable Non-Small Cell Lung Cancer (IMPRINT Study): A Single-Arm Open Label Feasibility Study' on Sept. 30.

Study Type: Interventional

Study Design: Purpose: Treatment Allocation: Non-randomised trial Masking: Open (masking not used) Assignment: Single group Type of endpoint: Safety/efficacy

Primary Sponsor: Royal Melbourne Hospital

Condition: non-small cell lung cancer non-small cell lung cancer Cancer - Lung - Non small cell

Intervention: This study will determine if bronchoscopic thermal ablati...